ロード中...
A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
The purpose of this prospective phase II clinical trial was to investigate the efficacy and safety of anlotinib in patients with relapsed small cell lung cancer (SCLC). Forty‐five patients with relapsed SCLC were enrolled and treated with anlotinib (one cycle of 12 mg daily for 14 days, discontinued...
保存先:
| 出版年: | Int J Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7689882/ https://ncbi.nlm.nih.gov/pubmed/32557583 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33161 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|